Radioresistant Nasopharyngeal Carcinoma Cells Exhibited Decreased Cisplatin Sensitivity by Inducing SLC1A6 Expression
Copyright © 2021 Hao, Wu, Cao, Yu, Ning, Wang, Lin and Chen..
Cisplatin-based regimens are commonly used for the treatment of nasopharyngeal carcinoma (NPC) in patients who receive concurrent chemoradiotherapy. The sensitivity of NPC cells to cisplatin is closely associated with the efficacy of radiation therapy. In this study, we established two radioresistant NPC cell lines, HONE1-IR and CNE2-IR, and found that both cell lines showed reduced sensitivity to cisplatin. RNA-sequence analysis showed that SLC1A6 was upregulated in both HONE1-IR and CNE2-IR cell lines. Downregulation of SLC1A6 enhanced cisplatin sensitivity in these two radioresistant NPC cell lines. It was also found that the expression of SLC1A6 was induced during radiation treatment and correlated with poor prognosis of NPC patients. Notably, we observed that upregulation of SLC1A6 led to elevating level of glutamate and the expression of drug-resistant genes, resulted in reduced cisplatin sensitivity. Our findings provide a rationale for developing a novel therapeutic target for NPC patients with cisplatin resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 12(2021) vom: 25., Seite 629264 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hao, Wenwen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Revised 02.05.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2021.629264 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324808518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324808518 | ||
| 003 | DE-627 | ||
| 005 | 20231225191113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2021.629264 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324808518 | ||
| 035 | |a (NLM)33927617 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hao, Wenwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radioresistant Nasopharyngeal Carcinoma Cells Exhibited Decreased Cisplatin Sensitivity by Inducing SLC1A6 Expression |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.05.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Hao, Wu, Cao, Yu, Ning, Wang, Lin and Chen. | ||
| 520 | |a Cisplatin-based regimens are commonly used for the treatment of nasopharyngeal carcinoma (NPC) in patients who receive concurrent chemoradiotherapy. The sensitivity of NPC cells to cisplatin is closely associated with the efficacy of radiation therapy. In this study, we established two radioresistant NPC cell lines, HONE1-IR and CNE2-IR, and found that both cell lines showed reduced sensitivity to cisplatin. RNA-sequence analysis showed that SLC1A6 was upregulated in both HONE1-IR and CNE2-IR cell lines. Downregulation of SLC1A6 enhanced cisplatin sensitivity in these two radioresistant NPC cell lines. It was also found that the expression of SLC1A6 was induced during radiation treatment and correlated with poor prognosis of NPC patients. Notably, we observed that upregulation of SLC1A6 led to elevating level of glutamate and the expression of drug-resistant genes, resulted in reduced cisplatin sensitivity. Our findings provide a rationale for developing a novel therapeutic target for NPC patients with cisplatin resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SLC1A6 | |
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a glutamate | |
| 650 | 4 | |a nasopharyngeal carcinoma | |
| 650 | 4 | |a radiation-resistance | |
| 700 | 1 | |a Wu, Lisha |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Linhui |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jinxiu |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jingshu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yanfeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 12(2021) vom: 25., Seite 629264 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:25 |g pages:629264 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2021.629264 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |b 25 |h 629264 | ||